Prescient Therapeutics Ltd - Prescient Therapeutics (PTX:ASX) Announces Three Internal OmniCAR Programs for Next-Gen CAR-T Therapies
Prescient Therapeutics Ltd (ASX:PTX)

Prescient Therapeutics (PTX:ASX) Announces Three Internal OmniCAR Programs for Next-Gen CAR-T Therapies

Published Jan 18, 2021

What happened?


What's happened?

Prescient Therapeutics (ASX:PTX) today announced three new internal development programs for OmniCAR, it's next-generation CAR-T cancer therapy platform, which they believe may possess distinct advantages over existing CAR-T therapies.

What are the key highlights?

  • Prescient Therapeutics announced OmniCAR, a universal immune receptor technology platform that offers numerous potential benefits over existing CAR-T therapies, with these benefits mainly pertaining to control, safety, flexibility, and efficacy.
  • The announcement follows a strategic review led by Prescient and its Scientific Advisory Board where all known CAR-T programs in development worldwide were taken into consideration. In the review, Prescient also called on the additional input and contribution of a number of leaders stemming from a diverse range of disciplines.
  • The announcement focused primarily on three internal programs which Prescient believes represent significant market opportunities. While current-generation CAR-T have faced challenges, OmniCAR may have distinct advantages.
  • The three development programs announced are "OmniCAR CD33 and CLL-1 for Acute Myeloid Leukemia (AML)", "OmniCAR Her2 for Her2+ solid tumours including breast, ovarian and gastric cancer"; and finally, "OmniCAR Her 2 and EGFRviii for Glioblastoma Multiforme (GBM)".

file

CEO's summary

Steven Yatomi-Clarke CEO of Prescient Therapeutics Ltd has provided a statement.
Steven Yatomi-Clarke
Steven Yatomi-Clarke
CEO, Prescient Therapeutics Ltd

We are delighted to select these internal programs as truly differentiated, next-generation CAR-T products for Prescient. Each of the programs represent a tremendous market opportunity.

Furthermore, Prescient will continue to seek collaborations with external parties on additional opportunities where OmniCAR can create additional next-generation CAR therapies with partners.

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Prescient Therapeutics (PTX:ASX) Reports Quarterly Results and Operating Highlights
What has happened? Prescient Therapeutics (PTX:ASX) announced their second-quarter activities and cashflow report which...
3 years ago
Around the web
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
Highlights PTX-100 Phase 1b trial in r/r TCL has been completed with encouraging results. Phase...
via kalkinemedia.com
Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
Highlights Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate fo...
via kalkinemedia.com
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Highlights PTX is advancing its diversified pipeline of cancer therapies, backed by a world-clas...
via kalkinemedia.com
Powered by  
  • Code
    ASX:PTX
View Prescient Therapeutics Ltd's Profile

How do I invest?

Considering investing in Prescient Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:PTX

    On your online investment platform search for the stock ticker code ASX:PTX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up